William B. Donnellan

The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results

David A. Sallman, Adam S. Asch, Monzr M. Al Malki et al. · Blood · 2019 · 220 citations

Medicine, Immunology, Pharmacology +11

KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results

Bijal Shah, Michael R. Bishop, Olalekan O. Oluwole et al. · Blood · 2021 · 200 citations · Full text

Medicine, Hematology, Oncology +16

Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)

David P. Steensma, Martin Wermke, Virginia M. Klimek et al. · Blood · 2019 · 89 citations

Medicine, Genetics, Hematology +14

Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: Phase Ib results.

David A. Sallman, Monzr Al Malki, Adam S. Asch et al. · Journal of Clinical Oncology · 2020 · 82 citations

Medicine, Immunology, Pharmacology +17

The first-in-class anti-CD47 antibody Hu5F9-G4 is active and well tolerated alone or with azacitidine in AML and MDS patients: Initial phase 1b results.

David A. Sallman, William B. Donnellan, Adam S. Asch et al. · Journal of Clinical Oncology · 2019 · 65 citations

Medicine, Oncology, Pharmacology +17